Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBIT (2020 - 2025)

Historic EBIT for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.1 million.

  • Tango Therapeutics' EBIT rose 14280.07% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 2101.89%. This contributed to the annual value of -$145.6 million for FY2024, which is 2752.14% down from last year.
  • Per Tango Therapeutics' latest filing, its EBIT stood at $14.1 million for Q3 2025, which was up 14280.07% from -$41.0 million recorded in Q2 2025.
  • Tango Therapeutics' EBIT's 5-year high stood at $14.1 million during Q3 2025, with a 5-year trough of -$42.5 million in Q1 2025.
  • Over the past 5 years, Tango Therapeutics' median EBIT value was -$29.6 million (recorded in 2024), while the average stood at -$26.2 million.
  • Per our database at Business Quant, Tango Therapeutics' EBIT plummeted by 96515423.73% in 2021 and then surged by 14280.07% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' EBIT stood at -$22.0 million in 2021, then crashed by 39.04% to -$30.6 million in 2022, then dropped by 14.55% to -$35.0 million in 2023, then decreased by 16.84% to -$40.9 million in 2024, then skyrocketed by 134.4% to $14.1 million in 2025.
  • Its EBIT stands at $14.1 million for Q3 2025, versus -$41.0 million for Q2 2025 and -$42.5 million for Q1 2025.